Here's Why Investors Should Buy Alcon (ALC) Stock Right Now
https://www.zacks.com/stock/news/2249788/here-s-why-investors-should-buy-alcon-alc-stock-right-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2249788
Apr 03, 2024 - Strength in the Surgical and Vision Care businesses bodes well for Alcon (ALC).
0
Abbott (ABT) Faces Low Testing Demand, Currency Headwinds
https://www.zacks.com/stock/news/2251992/abbott-abt-faces-low-testing-demand-currency-headwinds?cid=CS-ZC-FT-analyst_blog|zer_report_update-2251992
Apr 08, 2024 - Abbott's (ABT) core laboratory diagnostics business is gaining strength on the continued success of the Alinity suite of diagnostics instruments, along with a broad test menu offering.
0
Labcorp (LH) Extends MRD Clinical Research With New Launch
https://www.zacks.com/stock/news/2252021/labcorp-lh-extends-mrd-clinical-research-with-new-launch?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2252021
Apr 08, 2024 - Labcorp (LH) Plasma Detect MRD solution advances its leadership in precision oncology across the solid tumor oncology care continuum.
0
Smith+Nephew (SNN) Expands in Australia With New Alliance
https://www.zacks.com/stock/news/2253858/smith-nephew-snn-expands-in-australia-with-new-alliance?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2253858
Apr 11, 2024 - The latest partnership allows Smith+Nephew (SNN) to complement its existing implant range with the cutting-edge navigation technology of NAVBIT.
0
Here's Why You Should Retain Charles River (CRL) Stock Now
https://www.zacks.com/stock/news/2256314/here-s-why-you-should-retain-charles-river-crl-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2256314
Apr 16, 2024 - Investors are optimistic about Charles River (CRL) owing to strength in RMS and DSA segments.
0
Here's Why You Should Retain Chemed (CHE) Stock for Now
https://www.zacks.com/stock/news/2257026/here-s-why-you-should-retain-chemed-che-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2257026
Apr 17, 2024 - Investors are optimistic about Chemed (CHE), backed by the strong performance of the VITAS Healthcare and Roto-Rooter segments.
0
Henry Schein (HSIC) Global Presence Aids, Macroeconomic Woes Stay
https://www.zacks.com/stock/news/2257016/henry-schein-hsic-global-presence-aids-macroeconomic-woes-stay?cid=CS-ZC-FT-analyst_blog|zer_report_update-2257016
Apr 17, 2024 - Henry Schein (HSIC) is busy promoting digital workflows for general dentistry and dental specialties.
0
SYK vs ZBH: Which Stock Looks More Promising Ahead of Q1 Earnings?
https://www.zacks.com/stock/news/2261546/syk-vs-zbh-which-stock-looks-more-promising-ahead-of-q1-earnings?cid=CS-ZC-FT-analyst_blog|investment_ideas-2261546
Apr 24, 2024 - SYK and ZBH are expected to have witnessed strong procedural volume growth across the global market in the first quarter.
0